|
1
|
Curado M, Edwards B, Shin H, Storm H,
Ferlay J, Heanue M and Boyle P: Cancer incidence in five
continents. IX. IARC Scientific Publications; Lyon: 2007
|
|
2
|
Lloyd R and De Lellis R P H: World health
organization classification of tumours: Pathology and genetics of
tumours of the endocrine organs. IARC Press International Agency
for Research on Cancer; Lyon, France: 2004
|
|
3
|
Leenhardt L, Grosclaude P and
Cherié-Challine L: Thyroid Cancer Committee: Increased incidence of
thyroid carcinoma in france: A true epidemic or thyroid nodule
management effects? Report from the French thyroid cancer
committee. Thyroid. 14:1056–1060. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roti E, Uberti EC degli, Bondanelli M and
Braverman LE: Thyroid papillary microcarcinoma: A descriptive and
meta-analysis study. Eur J Endocrinol. 159:659–673. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Besic N, Pilko G, Petric R, Hocevar M and
Zgajnar J: Papillary thyroid microcarcinoma: Prognostic factors and
treatment. J Surg Oncol. 97:221–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mazzaferri EL: Management of low-risk
differentiated thyroid cancer. Endocr Pract. 13:498–512. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frasca F, Nucera C, Pellegriti G, Gangemi
P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et
al: BRAF(V600E) mutation and the biology of papillary thyroid
cancer. Endocr Relat Cancer. 15:191–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Riesco-Eizaguirre G and Santisteban P: New
insights in thyroid follicular cell biology and its impact in
thyroid cancer therapy. Endocr Relat Cancer. 14:957–977. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xing M: BRAF mutation in papillary thyroid
cancer: Pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu D, Liu Z, Condouris S and Xing M: BRAF
V600E maintains proliferation, transformation, and tumorigenicity
of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol
Metab. 92:2264–2271. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
AJCC, . American joint committee of
cancer, AJCC cancer staging manual. seventh. Springer; Chicago:
2010
|
|
14
|
Qiu T, Lu H, Guo L, Huang W, Ling Y, Shan
L, Li W, Ying J and Lv N: Detection of BRAF mutation in Chinese
tumor patients using a highly sensitive antibody
immunohistochemistry assay. Sci Rep. 5:92112015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X,
Ren X and Gao M: Papillary microcarcinoma of the thyroid: Clinical
characteristics and BRAF(V600E) mutational status of 977 cases. Ann
Surg Oncol. 20:2266–2273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guerra A, Fugazzola L, Marotta V, Cirillo
M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A and Vitale M:
A high percentage of BRAFV600E alleles in papillary thyroid
carcinoma predicts a poorer outcome. J Clin Endocrinol Metab.
97:2333–2340. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lim JY, Hong SW, Lee YS, Kim BW, Park CS,
Chang HS and Cho JY: Clinicopathologic implications of the
BRAF(V600E) mutation in papillary thyroid cancer: A subgroup
analysis of 3130 cases in a single center. Thyroid. 23:1423–1430.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim SJ, Lee KE, Myong JP, Park JH, Jeon
YK, Min HS, Park SY, Jung KC, Koo do H and Youn YK: BRAF V600E
mutation is associated with tumor aggressiveness in papillary
thyroid cancer. World J Surg. 36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y,
Zhang Y, Cheng W and Zhao W: Analysis of differential BRAF(V600E)
mutational status in high aggressive papillary thyroid
microcarcinoma. Ann Surg Oncol. 16:240–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi SY, Park H, Kang MK, Lee DK, Lee KD,
Lee HS, Kim SW, Lee EN and Hong JC: The relationship between the
BRAF(V600E) mutation in papillary thyroid microcarcinoma and
clinicopathologic factors. World J Surg Oncol. 11:2912013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee JH, Lee ES and Kim YS:
Clinicopathologic significance of BRAF V600E mutation in papillary
carcinomas of the thyroid: A meta-analysis. Cancer. 110:38–46.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smith RA, Salajegheh A, Weinstein S,
Nassiri M and Lam AK: Correlation between BRAF mutation and the
clinicopathological parameters in papillary thyroid carcinoma with
particular reference to follicular variant. Hum Pathol. 42:500–506.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu H, Qiu T, Ying J, Guo C and Lyn N:
Correlation between BRAF V600E mutation and clinicopathologic
features of papillary thyroid carcinoma. Zhonghua Bing Li Xue Za
Zhi. 43:794–798. 2014.(In Chinese). PubMed/NCBI
|
|
24
|
Tufano RP, Teixeira GV, Bishop J, Carson
KA and Xing M: BRAF mutation in papillary thyroid cancer and its
value in tailoring initial treatment: A systematic review and
meta-analysis. Medicine (Baltimore). 91:274–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lang BH, Chai YJ, Cowling BJ, Min HS, Lee
KE and Youn YK: Is BRAFV600E mutation a marker for central nodal
metastasis in small papillary thyroid carcinoma? Endocr Relat
Cancer. 21:285–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim SK, Song KH, Lim SD, Lim YC, Yoo YB,
Kim JS and Hwang TS: Clinical and pathological features and the
BRAF(V600E) mutation in patients with papillary thyroid carcinoma
with and without concurrent Hashimoto thyroiditis. Thyroid.
19:137–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Niemeier LA, Akatsu H Kuffner, Song C,
Carty SE, Hodak SP, Yip L, Ferris RL, Tseng GC, Seethala RR, Lebeau
SO, et al: A combined molecular-pathologic score improves risk
stratification of thyroid papillary microcarcinoma. Cancer.
118:2069–2077. 2012. View Article : Google Scholar : PubMed/NCBI
|
